Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]). We have recently shown an association between an immune-infiltrated tumor microenvironment (TME) and resistance to cyta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Uy, Geoffrey L., Aldoss, Ibrahim, Foster, Matthew C., Sayre, Peter H., Wieduwilt, Matthew J., Advani, Anjali S., Godwin, John E., Arellano, Martha L., Sweet, Kendra L., Emadi, Ashkan, Ravandi, Farhad, Erba, Harry P., Byrne, Michael, Michaelis, Laura, Topp, Max S., Vey, Norbert, Ciceri, Fabio, Carrabba, Matteo Giovanni, Paolini, Stefania, Huls, Gerwin A., Jongen-Lavrencic, Mojca, Wermke, Martin, Chevallier, Patrice, Gyan, Emmanuel, Récher, Christian, Stiff, Patrick J., Pettit, Kristen M., Löwenberg, Bob, Church, Sarah E., Anderson, Erica, Vadakekolathu, Jayakumar, Santaguida, Marianne, Rettig, Michael P., Muth, John, Curtis, Teia, Fehr, Erin, Guo, Kuo, Zhao, Jian, Bakkacha, Ouiam, Jacobs, Kenneth, Tran, Kathy, Kaminker, Patrick, Kostova, Maya, Bonvini, Ezio, Walter, Roland B., Davidson-Moncada, Jan K., Rutella, Sergio, DiPersio, John F.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885824/
https://ncbi.nlm.nih.gov/pubmed/32929488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007732
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares